1251863-44-1

Upstream product

• 116632-23-6 3-bromo-5-nitro-phenol 
• 915156-10-4 1-bromo-3-nitro-5-(propan-2-yloxy)benzene 

Downstream Products

• 1251863-18-9 1-{3-isopropoxy-5-[7-(4-methylimidazol-1-yl)imidazo[1,2-a]pyridin-3-yl]phenyl}-3-(2,2,2-trifluoroethyl)urea 
• 1251863-16-7 1-{3-isopropoxy-5-[7-(5-methyl[1,3,4]oxadiazol-2-yl)imidazo[1,2-a]pyridin-3-yl]phenyl}-3-(2,2,2-trifluoro-1-hydroxyethyl)urea 
• 1251863-15-6 {3-isopropoxy-5-[7-(5-methyl[1,3,4]oxadiazol-2-yl)imidazo[1,2-a]pyridin-3-yl]phenyl}urea 
• 1251863-14-5 1-{3-isopropoxy-5-[7-(4-isopropylpyrimidin-2-yl)imidazo[1,2-a]pyridin-3-yl]phenyl}-3-(2,2,2-trifluoroethyl)urea 
• 1251863-13-4 1-(3-{7-[4-(2-hydroxy-1,1-dimethylethyl)pyrimidin-2-yl]imidazo[1,2-a]pyridin-3-yl}-5-isopropoxyphenyl)-3-(2,2,2-trifluoroethyl)urea 
• 1251863-12-3 2-[2-(3-{3-isopropoxy-5-[3-(2,2,2-trifluoroethyl)ureido]phenyl}imidazo[1,2-a]pyridin-7-yl)pyrimidin-4-yl]-2-methylpropionic acid ethyl ester 
• 1251863-08-7 1-[3-isopropoxy-5-(7-[1,3,4]thiadiazol-2-ylimidazo[1,2-a]pyridin-3-yl)phenyl]-3-(2,2,2-trifluoroethyl)urea 
• 1251863-82-7 C₁₉H₂₀BF₃N₄O₄ 
• 1251863-81-6 C₁₉H₁₈ClF₃N₄O₂ 
• 1251863-67-8 C₂₆H₃₁F₃N₄O₅ 
• 1251863-09-8 1-{3-[7-(2-Hydroxy-ethoxy)-imidazo[1,2-a]pyridin-3-yl]-5-isopropoxy-phenyl}-3-(2,2,2-trifluoro-ethyl)-urea 
• 1251863-06-5 1-{3-Isopropoxy-5-[7-(5-methyl-[1,3,4]oxadiazol-2-yl)-imidazo[1,2-a]pyridin-3-yl]-phenyl}-3-(2,2,2-trifluoro-ethyl)-urea 
• 1251863-05-4 1-[3-Isopropoxy-5-(7-pyrimidin-2-yl-imidazo[1,2-a]pyridin-3-yl)-phenyl]-3-(2,2,2-trifluoro-ethyl)-urea 
• 1251900-04-5 C₃₁H₄₂F₃N₅O₄Si 

Relevant academic research and scientific papers

3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF

Disclosed herein is 3- [ (1H-pyrazol-4-yl) oxy] pyrazin-2-amine compounds of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of modulating, e.g., inhibiting or treating HPK1 related disorders or diseases including cancer by using the compound disclosed herein

MACROCYCLIC RIP2-KINASE INHIBITORS

The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of RIP2-kinase, and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of RIP2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.

Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold

Receptor-interacting protein kinase 2 (RIPK2) is a key mediator of nucleotide-binding oligomerization domain (NOD) cell signaling that has been implicated in various chronic inflammatory conditions. A new class of RIPK2 kinase/NOD signaling inhibitors bas

COMPOSITIONS FOR USE IN METHODS OF INHIBITING PROTEIN KINASES

Identified compounds demonstrate protein kinase inhibitory activity and inhibition of dependent cell signaling pathways, such as NOD2 cell signaling. More specifically, the compounds are demonstrated to inhibit receptor interacting kinase 2 (RIPK2) and/or Activin- like kinase 2 (ALK2). Compounds that are either dual RIPK2/ALK2 inhibitors or that preferentially inhibit RIPK2 or ALK2 could provide therapeutic benefit.

BICYCLIC HETEROCYCLYL DERIVATIVES AS FGFR KINASE INHIBITORS FOR THERAPEUTIC USE

The invention relates to new bicyclic heterocyclyl derivatives of formula (I), to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY

The invention relates to new bicyclic heterocyclyl derivatives of formula (I), to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.